© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
April 22, 2021
The genomic assay did not increase use of active surveillance in a predominantly African-American population of men with favorable-risk prostate cancer.
Exploration of the novel combination continues after early-phase published data showed promising clinical activity.
April 21, 2021
There were also no reports of sexual dysfunction related to device or procedure and no reported cases of sustained de novo erectile dysfunction at 5 years.
April 20, 2021
Padeliporfin ImPACT previously received FDA Fast Track and Orphan Drug designations for the treatment of patients with upper tract urothelial cancer.